Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an announcement.
Atomo Diagnostics Ltd. recently addressed a price query from the ASX, clarifying that they are unaware of any undisclosed price-sensitive information that could explain the recent trading activity in their securities. The company highlighted a recent purchase order for 65,000 HIV Self Test Kits for Ukraine, funded by USAID, but noted that the estimated revenue from this order does not meet their materiality threshold and thus was not announced on the ASX Market Announcements Platform. The company confirmed compliance with ASX disclosure rules and that their board authorized the responses.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, specializing in the development and supply of rapid diagnostic test kits. The company focuses on providing easy-to-use testing solutions for various health conditions, with a notable emphasis on HIV self-test kits.
Average Trading Volume: 2,027,031
Technical Sentiment Signal: Hold
Current Market Cap: A$17.82M
See more data about AT1 stock on TipRanks’ Stock Analysis page.